<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16432</article-id><article-id pub-id-type="doi">10.7554/eLife.16432</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Interferon Alpha-Inducible Protein 6 regulates NRASQ61K-induced melanomagenesis and growth</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-21453"><name><surname>Gupta</surname><given-names>Romi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55121"><name><surname>Forloni</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-65944"><name><surname>Bisseier</surname><given-names>Malik</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55122"><name><surname>Dogra</surname><given-names>Shaillay Kumar</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-65943"><name><surname>Yang</surname><given-names>Qiahong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3931"><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3306-349X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pathology</institution>, <institution>Yale University School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Singapore Institute of Clinical Sciences</institution>, <institution>Agency for Science Technology and Research</institution>, <addr-line><named-content content-type="city">Singapore</named-content></addr-line>, <country>Singapore</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1082"><name><surname>Espinosa</surname><given-names>Joaquín M</given-names></name><role>Reviewing editor</role><aff><institution>University of Colorado School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>narendra.wajapeyee@yale.edu</email> (NW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>08</day><month>09</month><year>2016</year></pub-date><volume>5</volume><elocation-id>e16432</elocation-id><history><date date-type="received"><day>28</day><month>03</month><year>2016</year></date><date date-type="accepted"><day>07</day><month>09</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Gupta et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Gupta et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-16432-v1.pdf"/><abstract><p>Mutations in the <italic>NRAS</italic> oncogene are present in up to 20% of melanoma. Here, we show that interferon alpha-inducible protein 6 (IFI6) is necessary for NRASQ61K-induced transformation and melanoma growth. <italic>IFI6</italic> was transcriptionally upregulated by NRASQ61K, and knockdown of <italic>IFI6</italic> resulted in DNA replication stress due to dysregulated DNA replication via E2F2. This stress consequentially inhibited cellular transformation and melanoma growth via senescence or apoptosis induction depending on the RB and p53 pathway status of the cells. NRAS-mutant melanoma were significantly more resistant to the cytotoxic effects of DNA replication stress-inducing drugs, and knockdown of <italic>IFI6</italic> increased sensitivity to these drugs. Pharmacological inhibition of <italic>IFI6</italic> expression by the MEK inhibitor trametinib, when combined with DNA replication stress-inducing drugs, blocked NRAS-mutant melanoma growth. Collectively, we demonstrate that IFI6, via E2F2 regulates DNA replication and melanoma development and growth, and this pathway can be pharmacologically targeted to inhibit NRAS-mutant melanoma.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA200919</award-id><principal-award-recipient><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21CA195077-01A1</award-id><principal-award-recipient><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21CA191364-01</award-id><principal-award-recipient><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21CA197758-01</award-id><principal-award-recipient><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance</institution></institution-wrap></funding-source><award-id>Pilot grant award</award-id><principal-award-recipient><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA196566</award-id><principal-award-recipient><name><surname>Wajapeyee</surname><given-names>Narendra</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the Yale University (IACUC protocol #2016-11333).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="datasets"><title>Major datasets</title><p/><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62827" source-id-type="uri"><collab>Gupta R</collab>, <collab>Forloni M</collab>, <collab>Dogra S</collab>, <collab>Wajapeyee N</collab>, <year>2016</year><x>,</x> <source>Transcriptional targets of oncogenic RAS proteins that mediate their ability to induce cellular transformation</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62827">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62827</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE62827)</comment></related-object><related-object content-type="generated-dataset" id="dataro2" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69933" source-id-type="uri"><collab>Gupta R</collab>, <collab>Forloni M</collab>, <collab>Dogra S</collab>, <collab>Wajapeyee N</collab>, <year>2016</year><x>,</x> <source>Regulators of NRAS-mediated transformation and melanoma tumor maintenance</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69933">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69933</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE69933)</comment></related-object></p></sec><supplementary-material><ext-link xlink:href="elife-16432-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>